Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Fennec Pharmaceuticals
FENC
Fennec Pharmaceuticals
Single Product Reliance Will Trigger Setbacks But Potential Remains
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
31 May 25
Updated
09 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$13.00
35.7% undervalued
intrinsic discount
09 Aug
US$8.36
Loading
1Y
50.4%
7D
0.4%
Author's Valuation
US$13.0
35.7% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$13.0
35.7% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-26m
103m
2014
2017
2020
2023
2025
2026
2028
Revenue US$102.7m
Earnings US$44.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
30.15%
Biotech revenue growth rate
13.11%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$44.11m
Earnings '28
x
10.05x
PE Ratio '28
=
US$443.12m
Market Cap '28
US$443.12m
Market Cap '28
/
28.40m
No. shares '28
=
US$15.60
Share Price '28
US$15.60
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$12.82
Fair Value '25
